Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Brivanib (alaninate)
Cat. No.:
OB0125LY-071
Appearance:
Solid
Purity:
99.6%
Identity:
Confirmed by NMR and LC-MS.
Size:
Add to basket
Product Overview
Description:
Brivanib (alaninate) is an inhibitor of both VEGF and FGF signaling pathways.
Synonym:
649735-63-7; Brivanib alaninate; BMS-582664; Brivanib (alaninate); [ (2R)-1-[4-[ (4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-yl] (2S)-2-aminopropanoate
CAS No.:
649735-63-7
Compound CID:
11154925
Formula:
C22H24FN5O4
Formula Weight:
441.46
Specification
Targets & IC50:
VEGFR2: 25 nM; FLK1: 89 nM; FGFR1: 148 nM; VEGFR1: 380 nM
Relative Density:
1.42 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Brivanib (alaninate) can be used for target discovery and drug screening.
Library Information
Targets:
VEGFR; FGFR; Autophagy
Receptors:
Autophagy; FGFR1; Flk1; VEGFR; VEGFR1; VEGFR2
Pathways:
Angiogenesis; Autophagy; Tyrosine kinase/adaptors
Plate Number:
AOCL-6
Plate Location:
e9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
82 mg/mL; 185.7 mM
Ethanol Max Solubility:
82 mg/mL; 185.7 mM
Saline Max Solubility:
9 mg/mL; 18.37 mM
ALogP:
3.383
HBA_Count:
6
HBD_Count:
2
Rotatable Bond:
8
